Ligand Pharmaceuticals Inc (LGND)
71.90
+0.44
(+0.62%)
USD |
NASDAQ |
May 02, 14:49
Ligand Pharmaceuticals Cash from Financing (Quarterly): 5.315M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 5.315M |
| September 30, 2023 | 3.27M |
| June 30, 2023 | -67.76M |
| March 31, 2023 | -0.775M |
| December 31, 2022 | -5.298M |
| September 30, 2022 | -40.83M |
| June 30, 2022 | -59.44M |
| March 31, 2022 | -170.42M |
| December 31, 2021 | 4.164M |
| September 30, 2021 | -0.385M |
| June 30, 2021 | -49.90M |
| March 31, 2021 | -91.64M |
| December 31, 2020 | -27.53M |
| September 30, 2020 | -3.706M |
| June 30, 2020 | -0.005M |
| March 31, 2020 | -279.30M |
| December 31, 2019 | -83.69M |
| September 30, 2019 | -211.31M |
| June 30, 2019 | -37.59M |
| March 31, 2019 | -152.58M |
| December 31, 2018 | -347.08M |
| September 30, 2018 | 58.92M |
| June 30, 2018 | 613.53M |
| March 31, 2018 | 3.224M |
| December 31, 2017 | -7.255M |
| Date | Value |
|---|---|
| September 30, 2017 | 1.404M |
| June 30, 2017 | -0.005M |
| March 31, 2017 | -1.667M |
| December 31, 2016 | -8.603M |
| September 30, 2016 | 1.629M |
| June 30, 2016 | 1.469M |
| March 31, 2016 | 0.511M |
| December 31, 2015 | 1.47M |
| September 30, 2015 | 1.46M |
| June 30, 2015 | 4.649M |
| March 31, 2015 | 0.781M |
| December 31, 2014 | -29.00M |
| September 30, 2014 | 162.32M |
| June 30, 2014 | -3.058M |
| March 31, 2014 | -0.241M |
| December 31, 2013 | -2.663M |
| September 30, 2013 | -2.048M |
| June 30, 2013 | -2.359M |
| March 31, 2013 | -9.388M |
| December 31, 2012 | 3.235M |
| September 30, 2012 | 1.439M |
| June 30, 2012 | 0.082M |
| March 31, 2012 | -0.84M |
| December 31, 2011 | 0.052M |
| September 30, 2011 | 0.002M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-279.30M
Minimum
Mar 2020
5.315M
Maximum
Dec 2023
-58.78M
Average
-37.59M
Median
Jun 2019
Cash from Financing (Quarterly) Benchmarks
| ANI Pharmaceuticals Inc | -11.92M |
| ADMA Biologics Inc | -38.99M |
| Viking Therapeutics Inc | 606.04M |
| Corcept Therapeutics Inc | 0.766M |
| Palatin Technologies Inc | 4.974M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 8.065M |
| Cash from Investing (Quarterly) | -10.28M |
| Free Cash Flow | -4.272M |
| Free Cash Flow Per Share (Quarterly) | -2.415 |
| Free Cash Flow to Equity (Quarterly) | -42.68M |
| Free Cash Flow to Firm (Quarterly) | -42.68M |
| Free Cash Flow Yield | -0.34% |